Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Click here to view

Presentation

Poster: Epigenetic Regulation of Human Prion Expression as a Potential One-Time Treatment for Prion Disease

Download PDF